ATE451926T1 - Zusammensetzung enthaltend einen hmg-coa- reduktasehemmer und eine nikotinsäureverbindung zur behandlung von hyperlipidämie - Google Patents

Zusammensetzung enthaltend einen hmg-coa- reduktasehemmer und eine nikotinsäureverbindung zur behandlung von hyperlipidämie

Info

Publication number: ATE451926T1
Authority: AT; Austria
Prior art keywords: nicotinic acid; nicotinamide; methyl; hmg; coa reductase
Prior art date: 1997-07-31

Application number

AT07003276T

Other languages

English (en)

Inventor

David J Bova

Josephine Dunne

Original Assignee

Abbott Respiratory Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-07-31

Filing date

1998-07-31

Publication date

2010-01-15

1998-07-31 Application filed by Abbott Respiratory Llc filed Critical Abbott Respiratory Llc

2010-01-15 Application granted granted Critical

2010-01-15 Publication of ATE451926T1 publication Critical patent/ATE451926T1/de

Links

PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Natural products OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 title abstract 7
239000011664 nicotinic acid Substances 0.000 title abstract 5
229960003512 nicotinic acid Drugs 0.000 title abstract 5
235000001968 nicotinic acid Nutrition 0.000 title abstract 4
-1 NICOTINIC ACID COMPOUND Chemical class 0.000 title abstract 3
239000000203 mixture Substances 0.000 title abstract 3
229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 2
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title abstract 2
208000031226 Hyperlipidaemia Diseases 0.000 title 1
IMRLNFKFNFLWQF-IYKITFJXSA-N sorbinicate Chemical compound O([C@H](COC(=O)C=1C=NC=CC=1)[C@@H](OC(=O)C=1C=NC=CC=1)[C@H](OC(=O)C=1C=NC=CC=1)[C@H](COC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)C(=O)C1=CC=CN=C1 IMRLNFKFNFLWQF-IYKITFJXSA-N 0.000 abstract 2
206010072268 Drug-induced liver injury Diseases 0.000 abstract 1
208000021642 Muscular disease Diseases 0.000 abstract 1
201000009623 Myopathy Diseases 0.000 abstract 1
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 abstract 1
KTLRWTOPTKGYQY-UHFFFAOYSA-N N-methyl-4-pyridone-3-carboxamide Chemical compound CN1C=CC(=O)C(C(N)=O)=C1 KTLRWTOPTKGYQY-UHFFFAOYSA-N 0.000 abstract 1
ZYVXHFWBYUDDBM-UHFFFAOYSA-N N-methylnicotinamide Chemical compound CNC(=O)C1=CC=CN=C1 ZYVXHFWBYUDDBM-UHFFFAOYSA-N 0.000 abstract 1
KUEUWHJGRZKESU-UHFFFAOYSA-N Niceritrol Chemical compound C=1C=CN=CC=1C(=O)OCC(COC(=O)C=1C=NC=CC=1)(COC(=O)C=1C=NC=CC=1)COC(=O)C1=CC=CN=C1 KUEUWHJGRZKESU-UHFFFAOYSA-N 0.000 abstract 1
USSFUVKEHXDAPM-UHFFFAOYSA-N Nicotinamide N-oxide Chemical compound NC(=O)C1=CC=C[N+]([O-])=C1 USSFUVKEHXDAPM-UHFFFAOYSA-N 0.000 abstract 1
206010039020 Rhabdomyolysis Diseases 0.000 abstract 1
DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
229940056243 aluminium nicotinate Drugs 0.000 abstract 1
NSFYKDVWNTWJOK-UHFFFAOYSA-K aluminum;pyridine-3-carboxylate Chemical compound [Al+3].[O-]C(=O)C1=CC=CN=C1.[O-]C(=O)C1=CC=CN=C1.[O-]C(=O)C1=CC=CN=C1 NSFYKDVWNTWJOK-UHFFFAOYSA-K 0.000 abstract 1
239000011248 coating agent Substances 0.000 abstract 1
238000000576 coating method Methods 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
238000013265 extended release Methods 0.000 abstract 1
239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
150000002632 lipids Chemical class 0.000 abstract 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
229960000827 niceritrol Drugs 0.000 abstract 1
NPORIZAYKBQYLF-LREBCSMRSA-N nicotinyl alcohol tartrate Chemical compound OCC1=CC=CN=C1.OC(=O)[C@H](O)[C@@H](O)C(O)=O NPORIZAYKBQYLF-LREBCSMRSA-N 0.000 abstract 1
229960000839 nicotinyl alcohol tartrate Drugs 0.000 abstract 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
210000002966 serum Anatomy 0.000 abstract 1
229950007581 sorbinicate Drugs 0.000 abstract 1
238000013268 sustained release Methods 0.000 abstract 1
239000012730 sustained-release form Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

AT07003276T 1997-07-31 1998-07-31 Zusammensetzung enthaltend einen hmg-coa- reduktasehemmer und eine nikotinsäureverbindung zur behandlung von hyperlipidämie ATE451926T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US90375297A	1997-07-31	1997-07-31

Publications (1)

Publication Number	Publication Date
ATE451926T1 true ATE451926T1 (de)	2010-01-15

Family

ID=25418027

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT98938228T ATE359785T1 (de)	1997-07-31	1998-07-31	Manteltablette enthaltend nikotinsäure oder einen stoff, der zu nikotinsäure metabolisiert wird, in verzögert freigesetzter form, und einen hmg-coa reduktasehemmer im mantel zur sofortigen freisetzung
AT07003276T ATE451926T1 (de)	1997-07-31	1998-07-31	Zusammensetzung enthaltend einen hmg-coa- reduktasehemmer und eine nikotinsäureverbindung zur behandlung von hyperlipidämie

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT98938228T ATE359785T1 (de)	1997-07-31	1998-07-31	Manteltablette enthaltend nikotinsäure oder einen stoff, der zu nikotinsäure metabolisiert wird, in verzögert freigesetzter form, und einen hmg-coa reduktasehemmer im mantel zur sofortigen freisetzung

Country Status (16)

Country	Link
US (3)	US20040053975A1 (de)
EP (2)	EP1792616B1 (de)
JP (2)	JP4870869B2 (de)
AT (2)	ATE359785T1 (de)
AU (1)	AU752673B2 (de)
BR (1)	BR9815548A (de)
CA (1)	CA2298549C (de)
CY (1)	CY1107057T1 (de)
DE (2)	DE69837610T2 (de)
DK (1)	DK1017390T3 (de)
ES (2)	ES2283067T3 (de)
IL (2)	IL134271A0 (de)
NO (1)	NO20000439L (de)
NZ (1)	NZ520176A (de)
PT (1)	PT1017390E (de)
WO (1)	WO1999006035A2 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE970731A1 (en) †	1997-10-07	2000-10-04	Fuisz Internat Ltd	Product and method for the treatment of hyperlipidemia
DE19858789A1 (de) *	1998-12-18	2000-06-21	Bayer Ag	Kombination von Cerivastatin und Fibraten
US6569461B1 (en)	1999-03-08	2003-05-27	Merck & Co., Inc.	Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
WO2001005408A1 (en) *	1999-07-14	2001-01-25	Geltex Pharmaceuticals, Inc.	Fat-binding polymers, optionally combined with lipase inhibitors
JP2001131151A (ja) *	1999-11-02	2001-05-15	Shionogi & Co Ltd	オレフィン誘導体の新規用途
IL139450A0 (en) *	1999-11-10	2001-11-25	Pfizer Prod Inc	Methods of administering apo b-secretion/mtp inhibitors
CZ20024015A3 (cs) †	2000-06-09	2003-04-16	Lek Pharmaceutical D.D.	Stabilní farmaceutický produkt a jeho formulace
CN1250212C (zh) *	2000-10-23	2006-04-12	三共株式会社	血中脂类改善剂组合物
US6916849B2 (en)	2000-10-23	2005-07-12	Sankyo Company, Limited	Compositions for improving lipid content in the blood
AU2002211005A1 (en) *	2000-11-07	2002-05-21	Sankyo Company Limited	Lipid peroxide-lowering compositions
TWI284529B (en) *	2000-12-18	2007-08-01	Sankyo Co	A composition for lowering triglyceride
US6982251B2 (en)	2000-12-20	2006-01-03	Schering Corporation	Substituted 2-azetidinones useful as hypocholesterolemic agents
DK1355644T3 (da)	2001-01-26	2006-10-23	Schering Corp	Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi
HU230253B1 (hu)	2001-01-26	2015-11-30	Merck Sharp & Dohme Corp	Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
US7071181B2 (en)	2001-01-26	2006-07-04	Schering Corporation	Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7056906B2 (en)	2001-09-21	2006-06-06	Schering Corporation	Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en)	2001-09-21	2006-05-30	Schering Corporation	Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
JP2005504091A (ja)	2001-09-21	2005-02-10	シェーリング　コーポレイション	ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
ITMI20012366A1 (it) *	2001-11-09	2003-05-09	Farmatron Ltd	Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali
US7176310B1 (en)	2002-04-09	2007-02-13	Ucb Sa	Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents
CN100415235C (zh) *	2002-08-02	2008-09-03	三共株式会社	含有HMG-CoA还原酶抑制剂的药物组合物
AU2003252358A1 (en) *	2002-08-02	2004-02-23	Sankyo Company, Limited	MEDICINAL COMPOSITION CONTAINING HMG-CoA REDUCTASE INHIBITOR
JP4607436B2 (ja) *	2002-08-02	2011-01-05	第一三共株式会社	ＨＭＧ−ＣｏＡリダクターゼ阻害剤を含有する医薬組成物
WO2004043457A1 (en)	2002-11-06	2004-05-27	Schering Corporation	Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
SI21402A (sl) *	2003-02-12	2004-08-31	LEK farmacevtska dru�ba d.d.	Obloženi delci in farmacevtske oblike
CA2517571C (en)	2003-03-07	2011-07-05	Schering Corporation	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2006519869A (ja)	2003-03-07	2006-08-31	シェーリング　コーポレイション	置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
US7459442B2 (en)	2003-03-07	2008-12-02	Schering Corporation	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP4589919B2 (ja)	2003-03-07	2010-12-01	シェーリングコーポレイション	高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
AR041089A1 (es) *	2003-05-15	2005-05-04	Merck & Co Inc	Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
BRPI0413363A (pt) *	2003-08-04	2006-10-10	Pfizer Prod Inc	formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase
WO2005041878A2 (en) *	2003-10-29	2005-05-12	Tawakol Raif M D	Compositions and methods for increasing hdl and hdl-2b levels
EP2805719A1 (de) *	2005-03-30	2014-11-26	Glaxosmithkline LLC	Nicotinamidribosid und Analoge davon
US20070014833A1 (en) *	2005-03-30	2007-01-18	Sirtris Pharmaceuticals, Inc.	Treatment of eye disorders with sirtuin modulators
US20060292099A1 (en) *	2005-05-25	2006-12-28	Michael Milburn	Treatment of eye disorders with sirtuin modulators
US20070149466A1 (en) *	2005-07-07	2007-06-28	Michael Milburn	Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
ATE548035T1 (de) *	2005-07-11	2012-03-15	Cortria Corp	Formulierungen zur behandlung von lipoprotein- anormalitäten mit einem statin- und einem methylnicotinamid-derivat
KR20070063350A (ko) *	2005-12-14	2007-06-19	주식회사종근당	서방형 방출층과 속방형 방출층을 포함한 고지혈증 및동맥경화를 치료를 위한 약제학적 조성물
CA2569776A1 (en) *	2006-02-17	2007-08-17	Kos Life Sciences, Inc.	Low flush niacin formulation
EP2081550B2 (de) *	2006-03-09	2021-05-26	Reliant Pharmaceuticals, Inc.	Beschichtung von kapseln mit pharmazeutischen wirkstoffen
US8784886B2 (en)	2006-03-09	2014-07-22	GlaxoSmithKline, LLC	Coating capsules with active pharmaceutical ingredients
WO2008023958A1 (en) *	2006-08-24	2008-02-28	Hanall Pharmaceutical Co., Ltd.	Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
WO2008023869A1 (en) *	2006-08-24	2008-02-28	Hanall Pharmaceutical Co., Ltd.	Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
DE102007003524A1 (de) *	2007-01-19	2008-09-04	MEDICE Arzneimittel Pütter GmbH & Co. KG	Arzneimittel zur Behandlung und/oder Prävention von Arteriosklerose
KR100885029B1 (ko)	2007-02-07	2009-02-23	지엘팜텍 주식회사	경구투여용 서방성 삼중정제
WO2009016577A2 (en) *	2007-07-27	2009-02-05	Ranbaxy Laboratories Limited	A pharmaceutical composition comprising atorvastatin and niacin
KR20090091075A (ko) *	2008-02-22	2009-08-26	한올제약주식회사	심혈관계 질환 치료용 약제학적 제제
EP2255797A4 (de) *	2008-02-22	2011-09-07	Hanall Biopharma Co Ltd	Komposit-herstellung
WO2009104939A2 (ko) *	2008-02-22	2009-08-27	한올제약주식회사	약제학적 제제
CN102083466A (zh) *	2008-05-20	2011-06-01	科莱尼斯医疗公司	用于组合疗法的烟酸和nsaid
WO2009149056A2 (en) *	2008-06-02	2009-12-10	Dr. Reddy's Laboratories Ltd.	Combinations of niacin and an oxicam
US20110123575A1 (en) *	2008-06-02	2011-05-26	Dr. Reddy's Laboratories Ltd.	Modified release niacin formulations
US20100178341A1 (en) *	2008-06-11	2010-07-15	Ranbaxy Laboratories Limited	BILAYERED TABLET COMPRISING NIACIN AND HMG-CoA REDUCTASE INHIBITOR
WO2010005581A1 (en) *	2008-07-11	2010-01-14	Kareus Therapeutics, Llc	Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of alzheimer's disease (ad)
RU2554740C2 (ru) *	2009-05-01	2015-06-27	Апталис Фарматек, Инк.	Композиции перорально распадающихся таблеток, содержащие комбинации высоко- и низкодозовых лекарственных средств
CA2706270C (en)	2010-06-03	2020-01-07	Accucaps Industries Limited	Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation
US20140294959A1 (en)	2011-05-20	2014-10-02	Astrazeneca Uk Limited	Pharmaceutical Composition of Rosuvastatin Calcium
WO2016077832A2 (en)	2014-11-14	2016-05-19	Gemphire Therapeutics Inc.	PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS
HK1257929A1 (zh) *	2015-11-06	2019-11-01	Gemphire Therapeutics Inc.	治疗混合性血脂异常
CA3059073A1 (en)	2017-04-18	2018-10-25	Gemphire Therapeutics Inc.	Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3524001A (en) *	1965-03-04	1970-08-11	Upjohn Co	Compositions and method for reducing free fatty acid and cholesterol in the blood of mammals with 3,5 - disubstituted isoxazoles
JPS63310827A (ja) *	1987-06-15	1988-12-19	Sanwa Kagaku Kenkyusho Co Ltd	ニコチン酸誘導体を主剤とする徐放性製剤
US5260305A (en) *	1988-12-12	1993-11-09	E. R. Squibb & Sons, Inc.	Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
US4933165A (en) *	1989-01-18	1990-06-12	Merck & Co., Inc.	Coenzyme Q10 with HMG-CoA reductase inhibitors
US5268181A (en) *	1989-04-13	1993-12-07	Upsher-Smith Laboratories, Inc.	Method of using niacin to control nocturnal cholesterol synthesis
CA2016467A1 (en) *	1989-06-05	1990-12-05	Martin Eisman	Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
CA2018470A1 (en) *	1989-07-17	1991-01-17	Scott Adams Biller	Phosphorus-containing squalene synthetase inhibitors and method
US5135935A (en) *	1991-05-17	1992-08-04	Merck & Co., Inc.	Squalene synthetase inhibitors
US5840339A (en) *	1991-07-30	1998-11-24	Kunin; Robert	Blood cholesterol reducing pharmaceutical composition
SG48108A1 (en) *	1991-11-22	1998-04-17	Lipogenenics Inc	Tocotrienols and tocotrienol-like compounds and methods for their use
US5292534A (en) *	1992-03-25	1994-03-08	Valentine Enterprises, Inc.	Sustained release composition and method utilizing xanthan gum and an active ingredient
US5609884A (en) *	1992-08-31	1997-03-11	G. D. Searle & Co.	Controlled release naproxen sodium plus naproxen combination tablet
US6080428A (en) *	1993-09-20	2000-06-27	Bova; David J.	Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6129930A (en) *	1993-09-20	2000-10-10	Bova; David J.	Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6369103B1 (en) *	1994-01-18	2002-04-09	Bristol-Myers Squibb Company	Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
US5582838A (en) *	1994-12-22	1996-12-10	Merck & Co., Inc.	Controlled release drug suspension delivery device
AU5787996A (en) *	1995-04-19	1996-11-07	Lipoprotein Technologies, Inc.	Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs
US5773453A (en) *	1995-04-19	1998-06-30	Vanderbilt University	Methods for administration of antilipemic drugs

1998
- 1998-07-31 EP EP07003276A patent/EP1792616B1/de not_active Expired - Lifetime
- 1998-07-31 AT AT98938228T patent/ATE359785T1/de active
- 1998-07-31 DE DE69837610T patent/DE69837610T2/de not_active Expired - Lifetime
- 1998-07-31 DK DK98938228T patent/DK1017390T3/da active
- 1998-07-31 CA CA002298549A patent/CA2298549C/en not_active Expired - Lifetime
- 1998-07-31 BR BR9815548-2A patent/BR9815548A/pt not_active Application Discontinuation
- 1998-07-31 NZ NZ520176A patent/NZ520176A/en not_active IP Right Cessation
- 1998-07-31 AU AU86801/98A patent/AU752673B2/en not_active Ceased
- 1998-07-31 ES ES98938228T patent/ES2283067T3/es not_active Expired - Lifetime
- 1998-07-31 AT AT07003276T patent/ATE451926T1/de not_active IP Right Cessation
- 1998-07-31 JP JP2000504849A patent/JP4870869B2/ja not_active Expired - Fee Related
- 1998-07-31 EP EP98938228A patent/EP1017390B1/de not_active Expired - Lifetime
- 1998-07-31 ES ES07003276T patent/ES2336492T3/es not_active Expired - Lifetime
- 1998-07-31 PT PT98938228T patent/PT1017390E/pt unknown
- 1998-07-31 DE DE69841395T patent/DE69841395D1/de not_active Expired - Lifetime
- 1998-07-31 WO PCT/US1998/015990 patent/WO1999006035A2/en not_active Ceased
- 1998-07-31 IL IL13427198A patent/IL134271A0/xx active IP Right Grant
2000
- 2000-01-27 NO NO20000439A patent/NO20000439L/no not_active Application Discontinuation
- 2000-01-27 IL IL134271A patent/IL134271A/en not_active IP Right Cessation
2003
- 2003-09-02 US US10/260,027 patent/US20040053975A1/en not_active Abandoned
2007
- 2007-05-07 CY CY20071100604T patent/CY1107057T1/el unknown
2009
- 2009-02-27 US US12/394,441 patent/US20090226518A1/en not_active Abandoned
- 2009-07-22 JP JP2009170721A patent/JP2009235105A/ja active Pending
2011
- 2011-10-27 US US13/282,755 patent/US20120164221A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20090226518A1 (en)	2009-09-10
BR9815548A (pt)	2000-11-07
DE69837610T2 (de)	2008-01-03
IL134271A0 (en)	2001-04-30
PT1017390E (pt)	2007-07-24
US20120164221A1 (en)	2012-06-28
CA2298549C (en)	2006-01-10
CY1107057T1 (el)	2012-10-24
WO1999006035A3 (en)	1999-04-22
JP4870869B2 (ja)	2012-02-08
IL134271A (en)	2006-07-05
ES2283067T3 (es)	2007-10-16
ATE359785T1 (de)	2007-05-15
DK1017390T3 (da)	2007-06-11
EP1792616B1 (de)	2009-12-16
NZ520176A (en)	2005-02-25
EP1017390B1 (de)	2007-04-18
DE69837610D1 (de)	2007-05-31
DE69841395D1 (de)	2010-01-28
ES2336492T3 (es)	2010-04-13
HK1106153A1 (en)	2008-03-07
JP2001511444A (ja)	2001-08-14
NO20000439L (no)	2000-03-22
JP2009235105A (ja)	2009-10-15
EP1017390A2 (de)	2000-07-12
CA2298549A1 (en)	1999-02-11
AU752673B2 (en)	2002-09-26
NO20000439D0 (no)	2000-01-27
EP1792616A1 (de)	2007-06-06
US20040053975A1 (en)	2004-03-18
AU8680198A (en)	1999-02-22
WO1999006035A2 (en)	1999-02-11

Legal Events

Date	Code	Title	Description
2010-06-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE451926T1 (de)	2010-01-15	Zusammensetzung enthaltend einen hmg-coa- reduktasehemmer und eine nikotinsäureverbindung zur behandlung von hyperlipidämie
NO973814L (no)	1997-10-13	Basisk stabilisert sammensetning av HMG-CoA-reduktase inhibitor
ATE149485T1 (de)	1997-03-15	Substituierte heterocyclische carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel
CA2356158A1 (en)	2000-07-06	Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
DE69600001D1 (de)	1997-02-27	Kosmetische Zusammensetzung, die eine Silikonverbindung und einen Fettsäureester enthält
NZ240946A (en)	1993-09-27	Substituted pyridyl-dihydroxy-heptenoic acid and amides thereof: preparation and medicaments thereof
DK1004578T3 (da)	2004-06-28	5-oxo-pyrrolidin-2-carboxylsyrehydroxamidderivater
ATE179710T1 (de)	1999-05-15	Substituierte pyrrole
KR970706807A (ko)	1997-12-01	메티오날 또는 말론디알데히드의 세포 내 비율에 영향을 미치는 성분을 함유하는 세포소멸(Capoptosis) 조절 조성물(APOPTOSIS-MODULATING COMPOSITION COMPRISING A FACTOR AFFECTING THE INTRACELLULAR RATE OF METHIONAL OR MALONDIALDEHYDE)
ATE212837T1 (de)	2002-02-15	Pharmazeutische zubereitung zur behandlung akuter rhinitiden, enthaltend sympthomimeticum und pantothenol und/oder pantothensäure
BR0317520A (pt)	2005-11-16	Composições de inibidores de proteìna de transferência de ésteres de colesterilo e inibidores de hmg-coa redutase
CA2344053A1 (en)	2000-03-23	Composition containing cinnamic acid derivatives for preventing or treating elevated blood lipid level-related diseases
DE69300062D1 (de)	1995-03-23	Verfahren zur Herstellung von N-Methoxyderivate von 4-Hydroxy-2,2,6,6-Tetramethylpiperidin und 2,2,6,6-Tetramethyl-4-Piperidon.
CA2301267A1 (en)	1999-02-25	Method of enhancing bioavailability of fexofenadine and its derivatives
DE59604829D1 (de)	2000-05-04	Kontinuierliches Verfahren zur Herstellung von 4-Amino-2,2,6,6-tetramethylpiperidin
ATE184007T1 (de)	1999-09-15	Substituierte pyrrole
TW355709B (en)	1999-04-11	Quinoline carboxylic acid derivative
KR880011104A (ko)	1988-10-26	치환된 피리딘-2,4-디카복실산유도체, 이의 제조방법, 이의 용도 및 이들 화합물을 기본으로 하는 약물
CA2385863A1 (en)	2001-04-12	New pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing these compounds
NO953322D0 (no)	1995-08-24	Anvendelse av 1,4-dihydropyridin-3,5-dikarboksylsyreestere som legemidler
CA2231588A1 (en)	1998-09-11	Process for the preparation of 4-(4-(4-(hydroxydiphenyl)-1-piperidinyl)-1-hydroxybutyl)-.alpha.,.alpha.-dimethylphenylacetic acid and phosphorylated derivatives
DE69405292D1 (de)	1997-10-09	6-Piperazinyl-1H-pyrazolo(3,4-b)pyridin-3-carbonsäuren, ihre Ester, Amide und verwandte Verbindungen, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
NO960777D0 (no)	1996-02-26	Anvendelse av N-alkylerte 1,4-dihydropyridin dikarboksylsyreestere som medikamenter
ES2106098T3 (es)	1997-11-01	Lacidipino para el tratamiento de la arteriosclerosis.
DE59306506D1 (de)	1997-06-26	4-Heterocyclyl substituierte Dihydropyridine